The pharmacokinetic–pharmacodynamic modelling framework as a tool to predict drug resistance evolution

C Witzany, J Rolff, RR Regoes, C Igler - Microbiology, 2023 - microbiologyresearch.org
Pharmacokinetic–pharmacodynamic (PKPD) models, which describe how drug
concentrations change over time and how that affects pathogen growth, have proven highly …

Revisiting the in-vitro and in-vivo considerations for in-silico modelling of complex injectable drug products

A Dabke, S Ghosh, P Dabke, K Sawant… - Journal of Controlled …, 2023 - Elsevier
Complex injectable drug products (CIDPs) have often been developed to modulate the
pharmacokinetics along with efficacy for therapeutic agents used for remediation of chronic …

C-Reactive protein as an early predictor of efficacy in advanced non-small-cell lung cancer patients: a tumor dynamics-biomarker modeling framework

YM Nassar, FW Ojara, A Pérez-Pitarch, K Geiger… - Cancers, 2023 - mdpi.com
Simple Summary In oncology, the identification of early predictors of response/survival is of
particular interest. C-reactive protein (CRP) concentrations have been associated with …

Hierarchical Bayesian pharmacometrics analysis of Baclofen for alcohol use disorder

N Baldy, N Simon, VK Jirsa… - … Learning: Science and …, 2023 - iopscience.iop.org
Alcohol use disorder (AUD), also called alcohol dependence, is a major public health
problem, affecting almost $10\% $ of the world's population. Baclofen, as a selective …

In vitro to in vivo acetaminophen hepatotoxicity extrapolation using classical schemes, pharmacodynamic models and a multiscale spatial-temporal liver twin

J Dichamp, G Cellière, A Ghallab, R Hassan… - … in Bioengineering and …, 2023 - frontiersin.org
In vitro to in vivo extrapolation represents a critical challenge in toxicology. In this paper we
explore extrapolation strategies for acetaminophen (APAP) based on mechanistic models …

Population pharmacokinetics and pharmacodynamics of carfilzomib in combination with rituximab, ifosfamide, carboplatin, and etoposide in adult patients with …

LH Lin, M Ghasemi, SM Burke, CK Mavis, JR Nichols… - Targeted Oncology, 2023 - Springer
Background In patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma
(DLBCL), salvage chemotherapy regimens (eg, rituximab, ifosfamide, carboplatin, and …

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists

C Hsin, J Dingemanse, A Henrich, C Bernaud, M Gehin… - Biomolecules, 2023 - mdpi.com
Background: The P2Y12 receptor antagonist selatogrel is being developed for
subcutaneous self-administration with a ready-to-use autoinjector at the onset of acute …

Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model

AL Jenner, W Kelly, M Dallaston, R Araujo… - PLOS Computational …, 2023 - journals.plos.org
The prognosis for pancreatic ductal adenocarcinoma (PDAC) patients has not significantly
improved in the past 3 decades, highlighting the need for more effective treatment …

Methotrexate Polyglutamates Exposure–Response Modeling in a Large Cohort of Rheumatoid Arthritis Patients Starting Methotrexate

RCF Hebing, IH Bartelink, HR Gosselt… - Clinical …, 2023 - Wiley Online Library
Methotrexate polyglutamates (MTX‐PG) concentrations in red blood cells (RBCs) have been
suggested as a biomarker of response in patients with rheumatoid arthritis (RA) receiving …

Robust and adaptive two-stage designs in nonlinear mixed effect models

L Fayette, R Leroux, F Mentré, J Seurat - The AAPS Journal, 2023 - Springer
To get informative studies for nonlinear mixed effect models (NLMEM), design optimization
can be performed based on Fisher Information Matrix (FIM) using the D-criterion. Its …